Regenxbio (RGNX) Stock Plummets 25% as FDA Halts Gene Therapy Trial

Regenxbio (RGNX) stock crashed 25% after FDA halted RGX-121 gene therapy trials due to spinal MRI findings in five patients treated years earlier.

The post Regenxbio (RGNX) Stock Plummets 25% as FDA Halts Gene Therapy Trial appeared first on Blockonomi.